Altimmune : NASH-TAG Conference 2022 Presentation

A placebo-controlled,double-blind,first-in-human study of pemvidutide (ALT-801), a novel GLP-1/glucagon dual receptor agonist for the treatment of NASH and obesity

1. Scott Harris1, John Nestor2, Joyce James3, Sarah K. Browne1, Jacques D. Payne1, Staci M. Steele1, Robert Casper1, Anvar Suyundikov1, Vyjayanthi Krishnan1, M. Scot Roberts1, Stephen A. Harrison4

1Altimmune, Inc, Gaithersburg, MD, USA; 2 Spitfire Pharma, South San Francisco, CA, USA;

3 Corvid, Oakland, CA, USA; 4 Pinnacle Research, San Antonio, TX, USA NASH-TAG, Park City, UT, January 2022

PEMVI: GLP-1/GLUCAGON

RECEPTOR DUAL AGONIST

O p t i m i z e d f o r w e i g h t l o s s a n d N A S H

Designed for significant reductions in:

BODY	LIVER FAT,	appetite
inflammation
WEIGHT	INFLAMMATION,
& RESULTING
	FIBROSIS	GLP-1

Indirect effects on liver

Direct effects on liver

GLUCAGON

energy expenditure adipose browning lipolysis mobilization of liver fat

DIETARY

2

PEMVI: RATIONALLY DESIGNED AND HIGHLY DIFFERENTIATED

D E S I G N E D W I T H T H E G O A L O F E N H A N C E D E F F I C A C Y A N D T O L E R A B I L I T Y W I T H O U T U S E O F D O S E T I T R AT I O N

Balanced

GLP-1: Glucagon

Agonism

			COOH
	VVVVVVVVVVVVVVVVVV	EuPort™ domain
						Prolonged half-life, longer time to peak concentration
Glucagon specificity						GLP-1 specificity
Improved weight loss						Restores metabolic function

Modified residue	Helix Stabilizer
Protease stability	Increased potency1

3	1Guarracino DA et al., Chem Rev. 2019 Sep 11;119(17):9915-9949

SUBSTANTIAL WEIGHT LOSS AT WEEK 12

1 0 . 3 % M E A N W E I G H T L O S S A C H I E V E D AT 1 . 8 M G D O S E

15

10

• Weight Loss

5

0

-5

Week 6

Week 12

***

10.3% **

9.0%

****

	5.4%			****	4.9%
				4.7%	1.6%

1.8%

-0.4%					pemvidutide				pemvidutide
	placebo			placebo
				1.2 mg 1.8 mg 2.4 mg				1.2 mg 1.8 mg 2.4 mg

4	** p < .01, ***p < .005, ****p < .001; compared to placebo

MAJORITY OF SUBJECTS AT 1.8 MG DOSE ACHIEVED 10% OR MORE WEIGHT LOSS AT WEEK 12

• 55% of subjects achieved 10% or more weight loss by Week 12

• 100% of subjects achieved 5% or more weight loss by Week 12

5